jig

jig@thebarn.com

1 participants
383 discussions

by Betsy Kremser

JIG meets Monday - usual time and place. NOTICE: Unless restricted by law, email correspondence to and from Anoka County government offices may be public data subject to the Minnesota Data Practices Act and/or may be disclosed to third parties.

14 years, 6 months

Dodge & Cox

by Betsy Kremser

Per our meeting on Monday, our holdings of Dodge & Cox were sold yesterday @38.34 per share for a realized gain of $382.95. NOTICE: Unless restricted by law, email correspondence to and from Anoka County government offices may be public data subject to the Minnesota Data Practices Act and/or may be disclosed to third parties.

14 years, 7 months

JIG Meets Monday

by Betsy Kremser

Reminder - JIG meets Monday at my house. Hope all have a happy Easter weekend! Betsy NOTICE: Unless restricted by law, email correspondence to and from Anoka County government offices may be public data subject to the Minnesota Data Practices Act and/or may be disclosed to third parties.

14 years, 7 months

Stents and Stocks

by Jim L. Ellingson

>From the Star and Sickle Good news for Medtronic, BoSci? Bruising battle shaping up in stents Article by: , Star Tribune Updated: April 5, 2011 - 4:49 PM Reports from a major meeting of cardiologists this week suggest a shift may be on the way in the market for drug-coated heart stents. Both Fridley-based Medtronic Inc. and Boston Scientific Corp. introduced results from separate studies indicating their next-generation stents are superior to older versions. Wells Fargo analyst Larry Biegelsen said in a note to investors that the evidence suggests that Medtronic and Boston Scientific's products could account for 21 to 23 percent of the $3.8 billion worldwide market by 2014. That means Illinois-based Abbott Laboratories' recent domination of the market will come under fire. Stents are tiny metal sleeves that prop open clogged heart arteries. When coated with drugs, vessels are less likely to reclog. Medtronic's stent, called Resolute, is the new version of its original Endeavor product. The stent is designed to release its drug into the body more slowly, preventing the artery from renarrowing and minimizing repeat treatments. The company's study involved 1,402 patients in the United States and found that 4.7 percent treated with the newer stent died for heart-related reasons, suffered a heart attack or needed retreatment within a year. The older Endeavor stent had a 6.5 percent rate of complications. The companies are presenting the data at the American College of Cardiology meeting in New Orleans. The Resolute stent is not yet available in the United States, but data from the study released Monday will be used to bolster the company's submission to the Food and Drug Administration (FDA) for approval. Medtronic says the FDA's decision is expected in the first half of 2012. Morgan Stanley analyst David Lewis said investors continue to "underappreciate the market potential" of the Resolute stent. "First-generation Endeavor was largely relegated to a niche market," he wrote, "but we believe Resolute will compete squarely" with rival stents from Boston Scientific and Abbott. The news failed to move Medtronic's stock Monday -- shares closed at $39.43, down 7 cents. A separate study involving 1,530 patients showed Boston Scientific's next-generation Promus Element stent is similar to earlier iterations of the device. The original version of Promus is identical to Xience, the market-leading stent made by Abbott -- part of a licensing agreement struck by the two companies when Boston Scientific bought Guidant Corp. in 2006. Death from cardiac causes, heart attacks and retreatment occurred in 3.4 percent of patients with the new Promus Element stent, compared with 2.9 percent of those treated with the older device. Rates of deadly clots in patients were identical at 0.4 percent, with re-treatment in 1.9 percent of patients in both groups. Showing similar clinical results to the existing Promus stent is important to Boston Scientific because the company's supply agreement with Abbott ends in mid-2012, analysts said. After that, the company will have to produce its own version of the product. Monday's study results will be used to pursue regulatory approval in the United States -- where the domestic market for drug-coated stents is now valued at more than $2 billion, according to the Millennium Research Group. Leerink Swann analyst Rick Wise said clinical results should "ease investor anxiety about [Boston Scientific's] ability to achieve FDA approval for Promus Element and successfully transition its Promus sales to Element." Boston Scientific's stock closed Monday at $7.23, down 7 cents. Dr. Martin Leon, of Columbia University/New York Presbyterian Hospital and lead researcher in the Medtronic study, said cardiologists will determine which device to use in patients based on subtle differences and personal preference. He compared the products to luxury automobiles made by Audi and BMW. "It's tough," he said. "These are all best-in-class." Bloomberg News contributed to this report. Janet Moore . 612-673-7752 -- ------------------------------ * Dr. James Ellingson, jellings(a)me.umn.edu * * mobile : 651/645-0753 * * Great Lakes Brewing News, 1569 Laurel Ave., St. Paul, MN 55104 * * james(a)brewingnews.com James.Ellingson(a)StThomas.edu *

14 years, 8 months

April JIG Meeting

by Betsy Kremser

The date of the April JIG meeting has been changed to April 25, 2011. The meeting will be at my house. Al - I will e-mail your Schedule K-1 via a secure e-mail. Betsy NOTICE: Unless restricted by law, email correspondence to and from Anoka County government offices may be public data subject to the Minnesota Data Practices Act and/or may be disclosed to third parties.

14 years, 8 months

JIG Meeting Tonight

by Betsy A. Kremser

JIG is scheduled to meet tonight at John and Karen's. We have a proxy from Maryellen. John & Karen Komp 10725 Jersey Dr. Brooklyn Park, MN 55445 John's Cell: 763-360-8800 Al - You're only paid up through January, so if you don't make it tonight, send me a check: Betsy Kremser 1373 Spencer Rd W Saint Paul, MN 55108 Betsy NOTICE: Unless restricted by law, email correspondence to and from Anoka County government offices may be public data subject to the Minnesota Data Practices Act and/or may be disclosed to third parties.

14 years, 9 months

JIG Avnet Purchase

by Betsy A. Kremser

The buy order we entered at last night's JIG meeting for 200 shares of Avenet, Inc. (AVT) was executed at $35.49 with a $9.99 commission fee for a total of $7,107.99. Betsy NOTICE: Unless restricted by law, email correspondence to and from Anoka County government offices may be public data subject to the Minnesota Data Practices Act and/or may be disclosed to third parties.

14 years, 10 months

JIG Meeting Monday at John and Karen's

by Betsy A. Kremser

Just a reminder that JIG meets Monday night at John and Karen's: 10725 Jersey Dr. N Brooklyn Park, MN 55445-2317 John's cell: 763-360-8800 NOTICE: Unless restricted by law, email correspondence to and from Anoka County government offices may be public data subject to the Minnesota Data Practices Act and/or may be disclosed to third parties.

14 years, 10 months

Jig at Johns on ???

by Jim L. Ellingson

Greetings, Way back when, last year and all, we decided to meet at John and Karen's. IS it tomorrow, aka MLK day? or is it a week from tomorrow Cheers, Jim -- ------------------------------ * Dr. James Ellingson, jellings(a)me.umn.edu * * mobile : 651/645-0753 * * Great Lakes Brewing News, 1569 Laurel Ave., St. Paul, MN 55104 * * james(a)brewingnews.com James.Ellingson(a)StThomas.edu *

14 years, 10 months

Dividend Stocks!: Mother of All Lists, Part II

by Betsy.Kremser＠co.anoka.mn.us

*Please note, the sender's email address has not been verified. Part II... ******************** If you are having trouble with any of the links in this message, or if the URL's are not appearing as links, please follow the instructions at the bottom of this email. Title: Dividend Stocks!: Mother of All Lists, Part II Copy and paste the following into your Web browser to access the sent link: http://www.emailthis.clickability.com/et/emailThis?clickMap=viewThis&etMail… Copy and paste the following into your Web browser to SAVE THIS link: http://www.savethis.clickability.com/st/saveThisPopupApp?clickMap=saveFromE… Copy and paste the following into your Web browser to forward this link: http://www.emailthis.clickability.com/et/emailThis?clickMap=forward&etMailT… ******************** Email pages from any Web site you visit - add the EMAIL THIS button to your browser, copy and paste the following into your Web browser: http://www.emailthis.clickability.com/et/emailThis?clickMap=browserButtons&…" ********************* Instructions: ----------------------------------------- If your e-mail program doesn't recognize Web addresses: 1. With your mouse, highlight the Web Address above. Be sure to highlight the entire Web address, even if it spans more than one line in your email. 2. Select Copy from the Edit menu at the top of your screen. 3. Launch your Web browser. 4. Paste the address into your Web browser by selecting Paste from the Edit menu. 5. Click Go or press Enter or Return on your keyboard. ********************

14 years, 11 months

← Newer
1
...
20
21
22
23
24
25
26
...
39
Older →

Jump to page:

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

jig